471 related articles for article (PubMed ID: 35605679)
1. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
Tarannum M; Vivero-Escoto JL
Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
3. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
4. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
Liu H; Shi Y; Qian F
Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
[TBL] [Abstract][Full Text] [Related]
5. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival.
Urbanova M; Cihova M; Buocikova V; Slopovsky J; Dubovan P; Pindak D; Tomas M; García-Bermejo L; Rodríguez-Garrote M; Earl J; Kohl Y; Kataki A; Dusinska M; Sainz B; Smolkova B; Gabelova A
Biomed Pharmacother; 2023 Sep; 165():115179. PubMed ID: 37481927
[TBL] [Abstract][Full Text] [Related]
6. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
7. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X
J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma.
Song H; Jiang C
Expert Opin Drug Deliv; 2022 Mar; 19(3):281-301. PubMed ID: 35220832
[TBL] [Abstract][Full Text] [Related]
9. Partial ligand shielding nanoparticles improve pancreatic ductal adenocarcinoma treatment via a multifunctional paradigm for tumor stroma reprogramming.
Zhao T; Zhang R; He Q; Zhou H; Song X; Gong T; Zhang Z
Acta Biomater; 2022 Jun; 145():122-134. PubMed ID: 35381402
[TBL] [Abstract][Full Text] [Related]
10. Novel systemic treatment approaches for metastatic pancreatic cancer.
Dorman K; Heinemann V; Kobold S; von Bergwelt-Baildon M; Boeck S
Expert Opin Investig Drugs; 2022 Mar; 31(3):249-262. PubMed ID: 35114868
[TBL] [Abstract][Full Text] [Related]
11. Activation of STING in the pancreatic tumor microenvironment: A novel therapeutic opportunity.
Chamma H; Vila IK; Taffoni C; Turtoi A; Laguette N
Cancer Lett; 2022 Jul; 538():215694. PubMed ID: 35489447
[TBL] [Abstract][Full Text] [Related]
12. Nanodiamond Mediated Molecular Targeting in Pancreatic Ductal Adenocarcinoma: Disrupting the Tumor-stromal Cross-talk, Next Hope on the Horizon?
Singh M; Pal P; Dutta RS; Marbaniang D; Ray S; Mazumder B
Curr Cancer Drug Targets; 2023; 23(8):620-633. PubMed ID: 36843367
[TBL] [Abstract][Full Text] [Related]
13. Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies.
Wang Z; Wu B; Nie G; Wei J; Li Y
Cancer Lett; 2023 Apr; 560():216138. PubMed ID: 36934836
[TBL] [Abstract][Full Text] [Related]
14. Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer.
Chen X; Zhou W; Liang C; Shi S; Yu X; Chen Q; Sun T; Lu Y; Zhang Y; Guo Q; Li C; Zhang Y; Jiang C
Nano Lett; 2019 Jun; 19(6):3527-3534. PubMed ID: 31058513
[TBL] [Abstract][Full Text] [Related]
15. Assessment and optimization of electroporation-assisted tumoral nanoparticle uptake in a nude mouse model of pancreatic ductal adenocarcinoma.
West DL; White SB; Zhang Z; Larson AC; Omary RA
Int J Nanomedicine; 2014; 9():4169-76. PubMed ID: 25214781
[TBL] [Abstract][Full Text] [Related]
16. Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin.
Chen W; Zhou Y; Zhi X; Ma T; Liu H; Chen BW; Zheng X; Xie S; Zhao B; Feng X; Dang X; Liang T
Biomaterials; 2019 Feb; 192():590-600. PubMed ID: 30553134
[TBL] [Abstract][Full Text] [Related]
17. Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma.
Joseph AM; Al Aiyan A; Al-Ramadi B; Singh SK; Kishore U
Front Immunol; 2024; 15():1323198. PubMed ID: 38384463
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies.
Natu J; Nagaraju GP
Cancer Lett; 2023 Oct; 573():216382. PubMed ID: 37666293
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities.
Qin Q; Yu R; Eriksson JE; Tsai HI; Zhu H
Cancer Lett; 2024 Jun; 591():216859. PubMed ID: 38615928
[TBL] [Abstract][Full Text] [Related]
20. Targeting Pancreatic Ductal Adenocarcinoma (PDAC).
Parrasia S; Zoratti M; Szabò I; Biasutto L
Cell Physiol Biochem; 2021 Jan; 55(1):61-90. PubMed ID: 33508184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
